

SAGER ERICH
Form 4
April 05, 2012

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
SAGER ERICH

(Last) (First) (Middle)

C/O RAPTOR
PHARMACEUTICAL CORP., 9
COMMERCIAL BLVD., SUITE 200

(Street)

NOVATO, CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

Raptor Pharmaceutical Corp [RPTP]

3. Date of Earliest Transaction
(Month/Day/Year)

04/02/2012

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	V	Amount				(A) or (D)	Price
Common Stock	04/02/2012 ⁽¹⁾		M			10,986	A	\$ 2.57	522,423	D	
Common Stock	04/02/2012 ⁽¹⁾		S			391	D	\$ 6.66	522,032	D	
Common Stock	04/02/2012 ⁽¹⁾		S			1,200	D	\$ 6.69	520,832	D	
Common Stock	04/02/2012 ⁽¹⁾		S			4,409	D	\$ 6.7	516,423	D	
Common Stock	04/02/2012 ⁽¹⁾		S			100	D	\$ 6.705	516,323	D	

Edgar Filing: SAGER ERICH - Form 4

Common Stock	04/02/2012 ⁽¹⁾	S	1,100	D	\$ 6.71	515,223	D
Common Stock	04/02/2012 ⁽¹⁾	S	2,100	D	\$ 6.72	513,123	D
Common Stock	04/02/2012 ⁽¹⁾	S	600	D	\$ 6.73	512,523	D
Common Stock	04/02/2012 ⁽¹⁾	S	900	D	\$ 6.74	511,623	D
Common Stock	04/02/2012 ⁽¹⁾	S	100	D	\$ 6.745	511,523	D
Common Stock	04/02/2012 ⁽¹⁾	S	423	D	\$ 6.75	511,100	D
Common Stock	04/02/2012 ⁽¹⁾	S	100	D	\$ 6.755	511,000	D
Common Stock	04/02/2012 ⁽¹⁾	S	200	D	\$ 6.76	510,800	D
Common Stock	04/02/2012 ⁽¹⁾	S	800	D	\$ 6.77	510,000	D
Common Stock	04/02/2012 ⁽¹⁾	S	100	D	\$ 6.775	509,900	D
Common Stock	04/02/2012 ⁽¹⁾	S	902	D	\$ 6.78	508,998	D
Common Stock	04/02/2012 ⁽¹⁾	S	886	D	\$ 6.79	508,112	D
Common Stock	04/02/2012 ⁽¹⁾	S	600	D	\$ 6.8	507,512	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable	Title

						Expiration Date	Amount or Number of Shares
Stock options (right to buy)	\$ 2.57	04/02/2012 ⁽¹⁾	M	10,986	11/26/2006 ⁽²⁾	05/25/2016	Common Stock 10,986

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SAGER ERICH C/O RAPTOR PHARMACEUTICAL CORP. 9 COMMERCIAL BLVD., SUITE 200 NOVATO, CA 94949	X			

Signatures

/s/ Kim R. Tsuchimoto, CFO, Raptor Pharmaceutical Corp.,
Attorney-in-fact

04/05/2012

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2012.
- (2) Original option grant vests 6/36ths on November 26, 2006 and 1/36th per month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.